Burundi
Tuberculosis profile
| High HIV burden |
Population  2013 10 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.3 (1.5–2.9) 22 (15–29)
Mortality (HIV+TB only) 0.6 (0.49–0.73) 5.9 (4.8–7.2)
Prevalence  (includes HIV+TB) 20 (11–31) 193 (104–309)
Incidence  (includes HIV+TB) 13 (12–14) 128 (119–139)
Incidence (HIV+TB only) 1.9 (1.8–2.1) 19 (18–21)
Case detection, all forms (%) 57 (53–62)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.6 (0.01–5.5) 13 (0.2–28)
MDR-TB cases among notified pulmonary
TB cases
140 (1–290) 38 (1–82)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 4 509   218
Pulmonary, clinically diagnosed 750   0
Extrapulmonary 1 990   0
       
Total new and relapse 7 467    
Previously treated, excluding relapses 80    
Total cases notified 7 547    
Among 7 249 new cases:
528 (7%) cases aged under 15 years; male:female ratio: 1.8
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 291 (6%) 0 (0%) 291
Laboratory-confirmed RR-/MDR-TB cases     59
Patients started on MDR-TB treatment     68
TB/HIV 2013 Number (%)
TB patients with known HIV status 6 581 (87)
HIV-positive TB patients 977 (15)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 931 (95)
HIV-positive TB patients on antiretroviral therapy (ART) 626 (64)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 89
Previously treated cases, excluding relapse, registered in 2012 81
HIV-positive TB cases, all types, registered in 2012 85
RR-/MDR-TB cases started on second-line treatment in 2011 90
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.7
Culture (per 5 million population) 0.5
Drug susceptibility testing (per 5 million population) 0.5
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 1.3
% Funded domestically 0%
% Funded internationally 100%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-07 Data: www.who.int/tb/data